

FIG. 1a



FIG. 1b

500000 20KV X4.00 7.5um




FIG.1c




FIG.1d




FIG. 2a




FIG. 2b




FIG. 2c




FIG. 2d

FIG. 2e

M S P T 41 62

kb
2.3—
9.4—
6.5—
4.3—
2.3—
2.0—
0.6—




FIG. 3




FIG. 4




FIG. 5




FIG. 6A

L1210 TARGETS (T)




FIG. 6B




FIG. 7




FIG. 8a







FIG. 8b





P1A




actin


1 2 3 4 5

FIG. 10


Insulin + hybridoma




allo MLR Proliferation




allo MLR IL-2



allo MLR +/- anti B7









A

- ▲ L1210/P815 (7X)
- ▼ L1210/HY38/GM-CSF (7X)
- ◆ P815/P815 (7X)
- P815/HY38/GM-CSF (3X)
- P815/HY38/GM-CSF (7X)


B

- ▼ untreated mice + P815 ascite
- surviving mice treated with HY38/GM-CSF (7X) + P815 ascite
- surviving mice treated with HY38/GM-CSF (3X) + P815 ascite






Proliferation of lymph node cells (Thymidin uptak)



Interleukin 2 secretion



Interferon gamma secretion

